Fatal COVID-19 in a Child with Persistence of SARS-CoV-2 Despite Extensive Multidisciplinary Treatment: A Case Report

Sofia Apostolidou, Theresa Harbauer, Peter Lasch, Daniel Biermann, Maja Hempel, Marc Lütgehetmann, Susanne Pfefferle, Jochen Herrmann, André Rüffer, Konrad Reinshagen, Rainer Kozlik-Feldmann, Anna Gieras, Inga Kniep, Jun Oh, Dominique Singer, Chinedu Ulrich Ebenebe and Robin Kobbe

Division of Neonatology and Pediatric Critical Care Medicine, University Children’s Hospital, University Medical Center Eppendorf, 20246 Hamburg, Germany; s.apostolidou@uke.de (S.A.); t.harbauer@uke.de (T.H.); d.singer@uke.de (D.S.); c.ebenebe@uke.de (C.U.E.)

Pediatric Intensive Care Medicine, Department of Pediatrics, Clinic Bremen-Mitte, Bremen Hospital Group, 28205 Bremen, Germany; Peter.Lasch@klinikum-bremen-mitte.de

Departments of Pediatric Cardiology and Pediatric Cardiac Surgery, Clinic for Children’s Heart Medicine, University Heart and Vascular Center Hamburg, 20466 Hamburg, Germany; d.biermann@uke.de (D.B.); a.rueffer@uke.de (A.R.); r.kozlik-feldmann@uke.de (R.K.-F.)

Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; m.hempel@uke.de

Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; m.luetgehetmann@uke.de (M.L.); s.pfefferle@uke.de (S.P.)

Section of Pediatric Radiology, Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Children’s Hospital, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; jherrmann@uke.de

Department of Pediatric Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; j.reinshagen@uke.de

Department of Immunology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; a.gieras@uke.de

Institute of Legal Medicine, University Medical Center Hamburg-Eppendorf, 22529 Hamburg, Germany; inga.kniep@uke.de

Department of Pediatric Nephrology, University Children’s Hospital, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; j.oh@uke.de

First Department of Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

*Correspondence: r.kobbe@uke.de; Tel.: +49-1-522-281-5646

Abstract: Critical Coronavirus disease 2019 (COVID-19) developed in a 7-year-old girl with a history of dystrophy, microcephaly, and central hypothyroidism. Starting with gastrointestinal symptoms, the patient developed severe myocarditis followed by progressive multiple organ failure complicated by *Pseudomonas aeruginosa* bloodstream infection. Intensive care treatment consisting of invasive ventilation, drainage of pleural effusion, and high catecholamine therapy could not prevent the progression of heart failure, leading to the implantation of venoarterial extracorporeal life support (VA-ECLS) and additional left ventricle support catheter (Impella® pump). Continuous venovenous hemofiltration (CVVH) and extracorporeal hemadsorption therapy (CytoSorb®) were initiated. Whole exome sequencing revealed a mutation of unknown significance in DExH-BOX helicase 30 (DHX30), a gene encoding a RNA helicase. COVID-19 specific antiviral and immunomodulatory treatment did not lead to viral clearance or control of hyperinflammation resulting in the patient’s death on extracorporeal life support-(ECLS)-day 20. This fatal case illustrates the potential severity of pediatric COVID-19 and suggests further evaluation of antiviral treatment strategies and vaccination programs for children.

Keywords: coronavirus disease 2019 (COVID-19); children; DExH-BOX helicase 30 (DHX30); extracorporeal life support (ECLS); Impella
1. Introduction

Symptomatic COVID-19 in children appears mostly mild or moderate, although Multisystem Inflammatory Syndrome in children (MIS-C) is the most frequent presentation among critically ill children with SARS-CoV-2 infection [1,2].

Since the beginning of the pandemic, only a few deaths in children with COVID-19 have been reported [3]. Analysis of child COVID-19 mortality in seven countries (USA, UK, Italy, Germany, Spain, France, and South Korea) up to February, 2021, show a low rate at 0.17 per 100,000 population. This comprises 0.48% of the estimated total mortality from all causes in a normal year, relatively more frequent in older children than younger age groups. No clear evidence of a trend of increasing mortality was detectable, but additional deaths have clearly occurred in children and young people during periods of high community transmission [4,5]. Currently, we are just beginning to understand whether specific risk factors or pre-existing medical conditions, as described in adults, are associated with severe disease and MIS-C in children [6,7].

2. Case Report

A seven-year-old female patient with headache, loss of appetite, abdominal pain, and vomiting for three days in the absence of cough, fever, or diarrhea was admitted to the regional hospital. The patient’s medical history was notable for late preterm birth, central hypothyroidism, failure to thrive (body weight 18 kg, <1. percentile), and recurrent respiratory tract infections. No laboratory tests to exclude primary immunodeficiency had been conducted previously. She attended a regular primary school. On admission, the patient was alert and showed mild signs of dehydration, but normal findings on abdominal, respiratory, cardiovascular, and neurologic examination. Laboratory tests (see Supplementary Material) revealed moderate signs of infection with elevated white blood cells, neutrophils, and C-reactive protein (CRP). The following day, she presented with increasing abdominal pain and distension, decreased peristaltic, free intraperitoneal fluid, and bilateral pleural and pericardial effusions on ultrasound examination. SARS-CoV-2 PCR from the nasopharyngeal swab sample was negative at this point.

2.1. Respiratory and Cardiovascular System

After referral to the municipal hospital on day 6 of illness, echocardiography revealed signs of myocarditis with significant impairment of the myocardial function (fractional shortening, FS 18%) and increased pericardial effusion. Due to increasing respiratory distress, non-invasive ventilation was initiated, and drainage of right pleural effusion mobilized 500 mL clear fluid. However, rapidly advancing respiratory failure led to intubation, and now SARS-CoV-2 PCR from tracheal aspirate was positive on day 7. The following days were marked by progressive multiple organ failure with acute respiratory distress syndrome (ARDS), cardiac failure requiring high-dose catecholamine therapy, and renal failure with oliguria and impaired glomerular filtration rate (GFR). Hypoxemic respiratory failure despite intensive, invasive ventilation therapy developed and persistent hypotension, due to cardiac failure, indicated a rescue therapy with ECLS. The patient was transferred to our University Medical Center, and with progressive cardiac failure (FS 10%) despite the maintenance of catecholamine therapy (milrinone, epinephrine, and norepinephrine), an ECLS, Impella® Heart Pump (Abiomed, Aachen Germany) was inserted via the ascending aorta for unloading of the left ventricle on day 20 after the onset of symptoms [8]. Impella® was discontinued, due to cardiac recovery after eight days of support and administration of Levosimendan for 48 hours. A myocardial biopsy confirmed the diagnosis of acute lymphocytic myocarditis—importantly, SARS-CoV-2 PCR from myocardial tissue was negative. Computed tomography of the chest on day 19 demonstrated diffuse, bilateral ground glass opacities with pulmonary consolidations, visible intralobular lines, and dilated subsegmental vessels. Application of pleural drainage continuously mobilized significant amounts of effusion over the next days. Notably, despite pronounced radiologic signs of pneumonia, a bronchoscopy performed on day 36 showed no significant...
pathology of the bronchopulmonary system, while lung biopsy showed diffuse alveolar damage, compatible with ARDS.

2.2. Anticoagulation and Transfusion Therapy

Intravenous therapeutic heparin infusion was conducted during ECLS therapy. Several blood products and anticoagulant drugs (fresh frozen plasma (FFP), platelet concentrates (PC), red blood cell concentrates (RBCC), PPSB, recombinant factor VIIa, and tranexamic acid) were administered, due to bleedings from cannula within the first 24 h after initiation, and several transfusions of FFP, PC, and RBCC were performed during ECLS therapy.

2.3. Renal Therapy

The patient developed acute kidney injury with oligo-anuria, possibly related to SARS-CoV-2 renal tropism, which represents a marker for multiorgan failure with a need for extracorporeal therapies in adults [9,10]. Diuretic therapy (furosemide and ethacrynic acid) was started on day 28 and supported by continuous venovenous hemofiltration (CVVH) from day 31. Kidneys appeared not enlarged, but signal intense on ultrasound, a biopsy was not performed.

2.4. Infection and Inflammation

Initial antimicrobial treatment with a cephalosporin was switched to ampicillin plus sulbactam, due to persisting laboratory signs of a bacterial infection with severe lymphopenia and a high neutrophil-lymphocyte ratio. In the absence of fever, a mandatory clinical sign of the diagnosis of MIS-C, a *Pseudomonas aeruginosa* bloodstream infection, was detected on day 21, and treated according to resistance testing. Due to the disease severity and persisting high SARS-CoV-2 RNA load in tracheal aspirate and blood measured by cobas 6800/8800 RT-PCR assay [11], the nucleotide analog prodrug remdesivir (5 mg/kg, followed by 2.5 mg/kg for ten days), an inhibitor of the viral RNA-dependent, RNA polymerase, was administered. Notably, the presence of a variant of concern was excluded [12]. Importantly, at different time points, neither IgM nor IgG antibodies against SARS-CoV-2 glycoprotein (S) or nucleoprotein (N) could be detected in two different serological assays (Elecsys, Roche, USA, DiaSorin Liaison, Germany). To boost antiviral activity, a total of 5 units (>1000 mL) of convalescent plasma (mean SARS-CoV-2 IgG 67.6 AU/mL, range 36.5–96.6) were transfused, but could not induce significant viral RNA clearance (Figure 1).

Despite the absence of fever, severe illness with multisystemic inflammation and especially COVID-19 associated myocarditis triggered MIS-C-like-disease treatment early in the disease course with repeated high-dose intravenous immunoglobulins and dexamethasone administration, followed by escalating doses of the interleukin-1 receptor antagonist anakinra to control inflammation. To further control systemic inflammatory response syndrome (SIRS), extracorporeal hemadsorption therapy (CytoSorb®, Cytosorbents, Berlin, Germany) was initiated on day 32, which temporally improved the clinical picture and reduced serum levels of IL-6, CRP, and Ferritin. Nevertheless, the patient’s circulatory system was continuously dependent on ECLS and inotropic support. As further deterioration after 14 days on ECLS with the persistence of hyperinflammation and ongoing SARS-CoV-2 replication seemed inevitable, we initiated antiviral interferon-γ treatment considering a monogenic disease with a candidate gene mutation in DHX30. Despite pronounced intensive care treatment, the patient died on day 20 on ECLS. Unfortunately, an autopsy was refused by the parents; therefore, additional exploration was only available by postmortem CT (PMCT), shown to be particularly useful in the current pandemic situation [13,14]. In our case, PMCT showed complete shadowing of the left lung with extensive consolidations and positive broncho-pneumogram, diffuse ground glass opacities, and extensive consolidations (Figure 2). The brain showed cerebral edema, while there were no signs of intracerebral bleeding.
**Table 1.** Clinical course with SARS-CoV-2 Viral load in nasopharyngeal swaps and blood. Abbreviations: DH = district hospital, N = non-invasive ventilation, CVVH = continuous veno-venous hemofiltration, CFRX = cefuroxime, C = convalescent plasma, ECH = extracorporeal hemadsorption, IFN-γ = interferon-γ.

| Day of illness | Location | SARS-CoV-2 PCR [copies/mL] | Respiratory | Cardiovascular | Renal | Analgesedation | Antimicrobials | COVID antiviral | COVID antinflammation |
|----------------|----------|----------------------------|-------------|----------------|-------|----------------|----------------|----------------|----------------------|
| 0              | Home     | negative                   | N           | Catecholamine therapy (epinephrine, norepinephrine, milrinone) | Furosemide + ethacrynic acid | Fentanyl + midazolam + ketamine + cisatracurium | CFRX | Remdesivir | Dexamethasone |
| 1              | DH       | positive (without quantification) | Extracorporeal membrane oxygenation | Ampicillin/sulbactam | Teicoplanin + meropenem + ceftazidime + imipenem + Liposomal amphotericin B | | | | |
| 2              | Regional Hospital | 10,000,000,000 | | | | | Remdesivir | Dexamethasone |
| 3              | University Medical Center | 1,000,000,000 | | | | | C | |
| 4              | | 100,000,000 | | | | | C | |
| 5              | | 10,000,000 | | | | | C | |
| 6              | | 1,000,000 | | | | | C | |
| 7              | | 100,000 | | | | | C | |
| 8              | | 10,000 | | | | | C | |
| 9              | | 1,000 | | | | | C | |

**Figure 1.** Clinical course with SARS-CoV-2 Viral load in nasopharyngeal swaps and blood. Abbreviations: DH = district hospital, N = non-invasive ventilation, CVVH = continuous veno-venous hemofiltration, CFRX = cefuroxime, C = convalescent plasma, ECH = extracorporeal hemadsorption, IFN-γ = interferon-γ.

**Figure 2.** Postmortem computed tomography (PMCT): (a) Coronary CT image (lung section); (b) axial CT image (lung section); patchy area of consolidation ventral (blue arrow); (c) axial CT image (section of head).
2.5. Genetic Examination

Before the COVID-19 infection, multiple genetic tests were performed to determine a genetic cause of primary microcephaly and dystrophy, revealing a normal female karyotype, inconspicuous results in Array-CGH and panel analysis. Rapid Trio-Whole-Exome-Sequencing (WES) showed a heterozygote *DHX30* variant (c.675T>A, p. (Ser225Arg)), also present in the healthy mother. To further explore the role of DHX30 in COVID-19, in vitro functional testing is underway.

3. Discussion

We report a case of critical COVID-19 in a 7-year-old girl with dystrophy, central hypothyroidism. Despite maximal intensive care treatment, including organ replacement procedures (ECLS, Impella®, hemofiltration, and hemadsorption therapy) and antiviral, as well as immunomodulatory therapies, the clinical course without viral clearance progressively worsened, leading to death 39 days after onset of disease and 20 days after initiation of ECLS.

Gastrointestinal symptoms marked the beginning of the illness, not fever or respiratory symptoms; this has been repeatedly described as a potential risk factor for critical COVID-19, especially in children with MIS-C [15]. Severe myocarditis leading to heart failure in our patient responded to the initiated therapy with ECLS and left-ventricular Impella® Heart Pump. The leading cause of mortality in adults is respiratory failure. Despite the recovery of cardiac function in our patient, the developing ARDS, supportively treated with ECLS and gentle ventilation, could not restore lung function. We assume persistent hyperinflammatory syndrome as the leading cause of pulmonary and multorgan failure concluding that mortality might be related to virologically driven hyperinflammation. Intravenous off-label use of remdesivir was started with 5 mg/kg on the first day, followed by 2.5 mg/kg daily, as suggested from Ebola treatment trials, and suggested for compassionate use in children and therapeutic drug monitoring of the prodrug. Elimination of remdesivir by hemadsorption using CytoSorb® devices has been reported [16]. Still, we structured procedures and drug application in a way so that the metabolite GS-441524 could be measured during ECLS and hemofiltration by the UHPLC-MS/MS method revealing target levels [17].

Twenty days after onset of symptoms, there were still no anti-SARS-CoV-2 antibodies detectable. Therefore, we used passive antibody transfer and transfused convalescent plasma on subsequent days without achieving viral clearance. Unfortunately, specific monoclonal antibodies directed against SARS-CoV-2 spike protein were not available in Germany.

Corticosteroids as immunosuppressive therapy in hyperinflammation syndrome have been shown to reduce mortality in adults, and selected IL-1 blockade with high dose anakinra has been recommended as a therapeutic option. In our hands, even in combination with CytoSorb®, this approach was not sufficient to establish control inflammation and thereby circulation. While the presence of anti-interferon autoantibodies was excluded, this unusual clinical development with the hallmark of high viral RNA loads and viremia gave rise to consider a pathogenic monogenetic disease [18,19]. Rapid Trio-WES could not detect an inborn error in the type I interferon-pathway [20], but detected a candidate heterozygote *DHX30* variant (c.675T>A, p. (Ser225Arg)). *DHX30* encodes for an RNA helicase that uses ATP hydrolysis to unwind RNA secondary structures and is required for most aspects of RNA metabolism and function [21]. Importantly, DHX30 interacts with ZAP (zinc-finger antiviral protein) and has been shown to restrict SARS-CoV-2. Therefore, a mutation in this highly conserved region might negatively affect RNA virus defense by insufficient interferon-γ [22]. Noteworthy, in the presence of severe lymphopenia, no natural killer cells or plasmacytoid dendritic cells could be detected. Acknowledging the possibility of interferon-γ deficiency [23], while judging the current situation of the patient doomed to deterioration, we decided to treat the patient with intravenous interferon-γ, hoping to boost antiviral potency and considering a worsening of the hyperinflammation. After
administration of interferon-γ in combination with convalescent plasma and high dose anakinra, viral RNA loads and hyperinflammation increased. Unfortunately, the patient died three days later with fulminant multiorgan-failure.

4. Conclusions

Although rare, COVID-19 with hyperinflammation in children can result in fatal organ damage despite maximal intensive care. Clinical trials testing antiviral strategies in children, and even more important, SARS-CoV-2 vaccination programs are urgently needed.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/children8070564/s1. Supplementary: laboratory data.

Author Contributions: S.A., C.U.E. and R.K., wrote the manuscript; S.A., C.U.E., T.H., P.L., A.R., K.R., R.K.-F., J.O., D.S. and R.K. were responsible for clinical care and acquisition of data; M.H., M.L., S.P., D.B., J.H., I.K. and A.G. for genetic, radiographic and microbiological analysis; all authors contributed substantially, and reviewed the final manuscript. First Author: S.A. is a consultant in pediatric intensive care and neonatology and head of our hospital’s analgosedation team (KAST). She was received the patient orientation and safety award from “Aktionsbündnis Patientensicherheit” (German Award of Patient safety). Her special interest is extracorporeal membrane oxygenation in children. Last author: R.K. is a consultant in pediatric infectious diseases and immunology, executive board member, German Association of Tropical Paediatrics and International Child Health “(GTP) and “Pediatric Infectious Disease Society” (DGPI). He holds the Diploma in Immunology and Pediatric Infectious Disease of the University Oxford (with Distinction) and the Diploma for Tropical Medicine and International Health. Currently, he is a member of STAKOB (Permanent Working Group of Competence and Treatment Centres for high consequence infectious diseases) and involved in clinical studies of therapeutic drugs and vaccines in infectious diseases including COVID19, HIV and tuberculosis. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The parents of the patient gave their written informed consent for the publication of this case report (ethic approval code PV3802).

Informed Consent Statement: Informed consent was obtained from the parents of the patient involved in the study.

Conflicts of Interest: The authors declare no funding or conflict of interest.

References
1. Götzinger, F.; Santiago-García, B.; Noguera-Julían, A.; Lanaspa, M.; Lancellis, L.; Carducci, F.I.C.; Gabrovská, N.; Velizarova, S.; Prunk, P.; Osterman, V.; et al. COVID-19 in children and adolescents in Europe: A multinational, multicentre cohort study. Lancet Child Adolesc. Health 2020, 4, 653–661. [CrossRef]
2. García-Salido, A.; de Carlos Vicente, J.C.; Hofheinz, S.B.; Ramirez, J.B.; Barrio, M.S.; Gordillo, I.L.; Yuste, A.H.; Pardellans, C.G.; Tejedor, M.C.-M.; Labarga, B.H.; et al. Severe manifestations of SARS-CoV-2 in children and adolescents: From COVID-19 pneumonia to multisystem inflammatory syndrome: A multicentre study in pediatric intensive care units in Spain. Crit. Care 2020, 24, 666. [CrossRef]
3. Dong, Y.; Mo, X.; Hu, Y.; Qi, X.; Jiang, F.; Jiang, Z.; Tong, S. Epidemiology of COVID-19 Among Children in China. Pediatrics 2020, 145, e20200702. [CrossRef] [PubMed]
4. Bhopal, S.S.; Bagaria, J.; Olabi, B.; Bhopal, R. COVID-19 deaths in children: Comparison with all- and other causes and trends in incidence of mortality. Public Health 2020, 188, 32–34. [CrossRef]
5. Bhopal, S.S.; Bagaria, J.; Olabi, B.; Bhopal, R. Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc. Health 2021, 5, e12–e13. [CrossRef]
6. Graff, K.; Smith, C.; Silveira, L.; Jung, S.; Curran-Hays, S.; Jarjour, J.; Carpenter, L.; Pickard, K.; Mattiucci, M.; Fresia, J.E.; et al. Risk Factors for Severe COVID-19 in Children. Pediatr Infect. Dis. J. 2021, 40, e137–e145. [CrossRef]
7. Abrams, J.Y.; Oster, M.E.; Godfred-Cato, S.E.; Bryant, B.; Datta, S.D.; Campbell, A.P.; Leung, J.W.; Tsang, C.A.; Pierce, T.J.; Kennedy, J.L.; et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: A retrospective surveillance study. Lancet Child Adolesc. Health 2021, 5, S2352–S4642. [CrossRef]
8. Parekh, D.; Jeewa, A.; Tume, S.C.; Dreyer, W.J.; Pignatelli, R.; Horne, D.; Justino, H.; Qureshi, A.M. Percutaneous Mechanical Circulatory Support Using Impella Devices for Decompensated Cardiogenic Shock: A Pediatric Heart Center Experience. ASAIO J. 2018, 64, 98–104. [CrossRef] [PubMed]
9. Braun, F.; Lütgehetmann, M.; Pfefferle, S.; Wong, M.N.; Carsten, A.; Lindenmeyer, M.T.; Norz, D.; Heinrich, F.; Meissner, K.; Wichmann, D.; et al. SARS-CoV-2 renal tropism associates with acute kidney injury. *Lancet* 2020, 396, 597–598. [CrossRef]

10. Ronco, C.; Reis, T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. *Nat. Rev. Nephrol.* 2020, 16, 308–310. [CrossRef]

11. Nörz, D.; Frontzek, A.; Eigner, U.; Oestereich, L.; Wichmann, D.; Kluge, S.; Fischer, N.; Aepfelbacher, M.; Pfefferle, S.; Lütgehetmann, M. Pushing beyond specifications: Evaluation of linearity and clinical performance of the cobas 6800/8800 SARS-CoV-2 RT-PCR assay for reliable quantification in blood and other materials outside recommendations. *J. Clin. Virol.* 2020, 132, 104650. [CrossRef] [PubMed]

12. Nörz, D.; Grunwald, M.; Olearo, F.; Fischer, N.; Aepfelbacher, M.; Pfefferle, S.; Lütgehetmann, M. Evaluation of a fully automated high-throughput SARS-CoV-2 multiplex qPCR assay with built-in screening functionality for del-HV69/70- and N501Y variants such as B.1.1.7. *J. Clin. Virol.* 2021, 141, 104894. [CrossRef] [PubMed]

13. Caturegli, G.; Cho, S.M.; White, B.; Chen, L.L. Acute Brain Injury in Infant Venoarterial Extracorporeal Membrane Oxygenation: An Autopsy Study. *Pediatr. Crit. Care Med.* 2021, 22, 297–302. [CrossRef] [PubMed]

14. Kniep, I.; Lutter, M.; Ron, A.; Edler, C.; Püschel, K.; Ittrich, H.; Heller, M.; Heinemann, A. Postmortale Bildgebung der Lunge bei COVID-19-Todesfällen [Postmortem imaging of the lung in cases of COVID-19 deaths]. *Radiologe* 2020, 60, 927–933. [CrossRef]

15. Sperotto, F.; Friedman, K.G.; Son, M.B.F.; VanderPluym, C.J.; Newburger, J.W.; Dionne, A. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: A comprehensive review and proposed clinical approach. *Eur. J. Pediatrics* 2021, 180, 307–322. [CrossRef] [PubMed]

16. Biever, P.; Staudacher, D.L.; Sommer, M.J.; Triebel, H.; Neukamm, M.A.; Bode, C.; Supady, A.; Lother, A. Hemadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19. *Pharmacol. Res. Perspect.* 2021, 9, e00743. [CrossRef]

17. Avantaneo, V.; de Nicolò, A.; Cusato, J.; Antonucci, M.; Manca, A.; Palermi, A.; Waitt, C.; Walimbwa, S.; Lamorde, M.; Di Perri, G.; et al. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: A tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. *J. Antimicrob. Chemother.* 2020, 75, 1772–1777. [CrossRef]

18. Nchioua, R.; Kmiec, D.; Müller, J.A.; Conzelmann, C.; Gross, R.; Swanson, C.M.; Stenger, S.; Sauter, D.; Munch, J.; et al. SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans. *mBio* 2020, 11, e01930-20. [CrossRef]

19. Bastard, P.; Rosen, L.B.; Zhang, Q.; Michailidis, E.; Hoffmann, H.-H.; Zhang, Y.; Dorgham, K.; Philippot, Q.; Rosain, J.; Beziat, V.; et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science* 2020, 370, eabd4585. [CrossRef]

20. Zhang, S.Y.; Zhang, Q.; Casanova, J.L.; Su, H.C.; The COVID Team. Severe COVID-19 in the young and healthy: Monogenic inborn errors of immunity? *Nat. Rev. Immunol.* 2020, 20, 455–456. [CrossRef]

21. Zhang, Q.; Bastard, P.; Liu, Z.; Le Pen, J.; Moncada-Velez, M.; Chen, J.; Ogishi, M.; Sabliti, I.K.D.; Hodeib, S.; Korol, C.; et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* 2020, 370, eabd4570. [CrossRef] [PubMed]

22. Lessel, D.; Schob, C.; Küry, S.; Reijnders, M.R.F.; Harel, T.; Eldomery, M.K.; Coban-Akdemir, Z.; Denecke, J.; Edvardsson, S.; Colin, E.; et al. De Novo Missense Mutations in DHX30 Impair Global Translation and Cause a Neurodevelopmental Disorder. *Am. J. Hum. Genet.* 2017, 101, 716–724. [CrossRef] [PubMed]

23. Meffre, E.; Iwasaki, A. Interferon deficiency can lead to severe COVID. *Nature* 2020, 587, 374–376. [CrossRef] [PubMed]